OncoMatch/Clinical Trials/NCT06663319
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Is NCT06663319 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including JNJ-89402638 and Bevacizumab for colorectal neoplasms.
Treatment: JNJ-89402638 · Bevacizumab · FOLFOX · FOLFIRI — The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) of JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MSH2 proficient mismatch repair
microsatellite stable (MSS) or proficient mismatch repair (pMMR) CRC
Required: MSH6 proficient mismatch repair
microsatellite stable (MSS) or proficient mismatch repair (pMMR) CRC
Required: MLH1 proficient mismatch repair
microsatellite stable (MSS) or proficient mismatch repair (pMMR) CRC
Required: PMS2 proficient mismatch repair
microsatellite stable (MSS) or proficient mismatch repair (pMMR) CRC
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy — metastatic/unresectable
progressing after 2 or more prior lines of standard therapy in the metastatic/unresectable setting
Must have received: standard therapy — metastatic/unresectable
progressing after 1 prior line of standard therapy in the metastatic/unresectable setting
Cannot have received: platinum-based chemotherapy (oxaliplatin)
Exception: must not have received oxaliplatin previously for metastatic disease (Part 2 Arm C)
Must not have received oxaliplatin previously for metastatic disease
Cannot have received: topoisomerase inhibitor (irinotecan)
Exception: must not have received irinotecan previously for metastatic disease (Part 2 Arm D)
Must not have received irinotecan previously for metastatic disease
Lab requirements
Kidney function
gfr >= 30 ml/min based on mdrd 4-variable formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Colorado Denver Anschultz Medical Campus · Aurora, Colorado
- Florida Cancer Specialists · Sarasota, Florida
- Community Health Network · Indianapolis, Indiana
- Start Midwest · Grand Rapids, Michigan
- Swedish Cancer Institute · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06663319 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior platinum-based chemotherapy, topoisomerase inhibitor disqualifies patients from enrollment.
Does this trial require MSH2?
Yes, MSH2 proficient mismatch repair is a required biomarker for enrollment.
Does this trial require MSH6?
Yes, MSH6 proficient mismatch repair is a required biomarker for enrollment.
Does this trial require MLH1?
Yes, MLH1 proficient mismatch repair is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify